UK health care workers begin COVID-19 hydroxychloroquine trial

UK health care workers begin COVID-19 hydroxychloroquine trial
The ‘COPCOV’ study will involve more than 40,000 frontline health care workers from Europe, Africa, Asia and South America. (File/AFP)
Short Url
Updated 21 May 2020

UK health care workers begin COVID-19 hydroxychloroquine trial

UK health care workers begin COVID-19 hydroxychloroquine trial
  • The trial will open to British participants at hospital sites in Brighton and Oxford
  • It will involve those who are in close contact with patients with proven or suspected COVID-19

LONDON: British health care workers will on Thursday begin taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one US President Donald Trump says he has been taking.
The ‘COPCOV’ study will involve more than 40,000 frontline health care workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine are effective in preventing the novel coronavirus.
The drugs have risen to prominence since Trump said earlier this week he was taking hydroxychloroquine as a preventive medicine against the virus despite medical warnings about its use.
The trial, led by the University of Oxford with the support of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, will open to British participants at hospital sites in Brighton and Oxford on Thursday and involve those who are in close contact with patients with proven or suspected COVID-19.
“We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19,” said the University of Oxford’s Professor Nicholas White, the study’s co-principal investigator who is based at MORU.
“The best way to find out if they are effective in preventing COVID-19 is in a randomised clinical trial,“
In Britain, Europe and Africa participants will receive either hydroxychloroquine or a placebo for three months. In Asia they will receive either chloroquine or a placebo.
A total of 25 study sites are expected to be open in the UK by the end of June, MORU said, with plans for further sites in Thailand and Southeast Asia, Italy, Portugal, Africa and South America. The results are expected by the end of this year.
“We are looking at this with great care and examining all of the evidence that is out there,” Britain’s security minister James Brokenshire told Sky News.


Safety fears hamper India’s COVID-19 vaccination drive

Safety fears hamper India’s COVID-19 vaccination drive
A medical worker inoculates a colleague with a COVID-19 coronavirus vaccine at the north central railway hospital in Allahabad on Friday. (AFP)
Updated 23 January 2021

Safety fears hamper India’s COVID-19 vaccination drive

Safety fears hamper India’s COVID-19 vaccination drive
  • Only half of the government’s target has been inoculated

NEW DELHI: The world’s biggest vaccination drive to inoculate 1.3 billion people against the coronavirus is slowing down in India as concerns over safety fuel vaccine hesitancy, especially among health workers.

Indian Prime Minister Narendra Modi launched the campaign on Jan. 16, with 30 million frontline health care workers the first to get the jab. A week into the drive, however, Health Ministry data suggest that on average only 150,000 people have been inoculated a day — half of the government’s target.
“There is a general hesitancy among healthcare workers, particularly doctors, about the efficacy of the vaccines,” Adarsh Pratap Singh, president of the Resident Doctors Association of the premier Delhi-based All India Institute of Medical Sciences (AIIMS), told Arab News on Friday.
Two coronavirus vaccines have been approved for emergency use in India: the Oxford-AstraZeneca vaccine produced domestically as Covishield by the Pune-based Serum Institute of India, and a locally developed vaccine called Covaxin, produced by Indian company Bharat Biotech, which is still in its trial stage and has no final data on its efficacy.
“Lack of transparency is at the core of vaccine hesitancy,” Dr. Nirmalya Mohapatra of Delhi-based Ram Manohar Lohia Hospital, told Arab News.
“We doctors should have jointly taken up the issue and asked the government to demonstrate more transparency in introducing the vaccine,” he said.
Mohapatra was one of the doctors who on Jan. 16 refused to take a Covaxin shot at his hospital.
Progressive Medicos and Scientists Forum (PMSF) president, Dr. Harjit Singh Bhattialso, says that the absence of data is fueling “fear about the vaccination” among members of the medical community.
 Concerns also exist about the Covishield vaccine.

FASTFACT

Instead of digital campaigns, some doctors say that Indian leaders themselves should get the jabs to inspire trust in vaccination.

“Even there is hesitancy about Covishied. There is no enthusiasm for it. However, people will prefer Covishied over Covaxin,” Bhatti said.
In response to vaccine hesitancy, Health Minister Dr. Harsh Vardhan on Thursday launched an information campaign to address what he said were “rumors and misinformation.”
“We have launched a digital media package with impactful messages from key technical experts from the country who have taken COVID-19 vaccine,” Vardhan told reporters.
The messages, he said, are that “vaccines are safe and efficacious,” and cover the “critical role of vaccines in controlling the pandemic.”
But instead of digital campaigns, some doctors say that Indian leaders themselves should get the jabs to inspire trust in vaccination.
“If the Indian PM Narendra Modi and other political high-ups take the vaccine then it will have a huge impact,” Singh said. “There is a lack of political consensus on vaccines. To inspire confidence all the state chief ministers should also take the shot.”
According to media reports, Modi may get vaccinated in the second phase of the campaign, in March or April, when 270 million people above the age of 50 will be inoculated.
Other health experts argue, however, that vaccinating leaders is not a substitute for scientific processes.
“Leadership taking the vaccine is more of a tokenism than coming out clean on the efficacy and the actual and effective profile of the vaccine,” said Amar Jesani, a Mumbai-based health expert and editor of the Indian Journal of Medical Ethics.
“What is tragic is that our PM might be ready to take the risk of vaccination (but) he is not ready to offend the companies, which are sitting on the data. Why can’t they make the data public? This is what the doctors are asking for,” he told Arab News.
In the absence of scientific data, he argued, people with underlying health problems would be hesitant to get vaccinated when the immunization campaign reaches the general public.
“When you are not transparent today, then tomorrow comorbid people will be hesitant and then the general population will be reluctant,” he said.